BOSTON — Combined results from two studies of an experimental Alzheimer's drug suggest it might modestly slow mental decline, especially in patients with mild disease.

Taken separately, the studies on the drug – Eli Lilly & Co.'s solanezumab – missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living. But pooled results found 34 percent less mental decline in mild Alzheimer's patients compared to those on a fake treatment for 18 months.